https://www.hcplive.com/view/biotherapeutic-ads024-safe-tolerable-recurrent-c-difficile-prevention
0
0
10/22/23 at 11:14pm
Organization
Hcplive.com
Author
Kevin Kunzmann
25 words
0
Comments
New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.
You are the first to view
Create an account
or login to join the discussion